Tsinghua University-BI Joint Research Center for Immunotherapy of Infectious Diseases" was established in July 2018 with the English name "Tsinghua University-Boehringer Ingelheim Joint Research Center for Immuno-Infection". The main purpose is to reflect the two key connotations of infection and immunotherapy. The research direction is mainly to explore the use of the latest immune methods to enhance the human body’s resistance to infectious diseases, that is, to achieve a broad-spectrum anti-infection goal by regulating the host’s immune system. The center will further promote the immunology and research of Tsinghua University School of Medicine The pace of discipline construction in the field of infectious diseases provides world-class resources from the industry for scientific research and talent training in these fields. Since its establishment, the Tsinghua University School of Medicine has maintained a stable and efficient development in scientific research achievements and talent training In order to further improve the quantity and quality of the transformation of scientific research results of the college, and explore the methods and ways of scientific research and technological innovation. As the main body of scientific research and innovation, the medical school can better integrate the resources of both parties through cooperation with enterprises, which will be more effective basis. The market environment transforms scientific research results into products that are beneficial to social development and people’s lives. At the same time, cooperation with companies can also provide more clinical trial opportunities for academic research, and companies can also feed clinical problems back to the laboratory for analysis. The solution has fundamentally improved the scientific research capabilities of the medical school and the core competitiveness of the enterprise.